Drugs / RILOGROTUG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05865535 | Jun 2023 → Dec 2026 expected | hypoproteinemia, hypercatabolic | AVEO Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04815551 | Feb 2021 → Jan 2022 | hypoproteinemia, hypercatabolic | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2015-04-20 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research aveooncology.com ↗
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. |
| 2014-09-26 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference aveooncology.com ↗
These studies demonstrate that elevated levels of circulating GDF15 drive the development of cancer cachexia in mice, and that its inhibition, with AV-380, completely reversed body weight loss and restored normal body composition, including fat, muscle and organ size. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-08-17 | AVEO Pharmaceuticals, Inc. | AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies aveooncology.com ↗ |
| 2015-04-20 | AVEO Pharmaceuticals, Inc. | AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research aveooncology.com ↗ |
| 2014-09-26 | AVEO Pharmaceuticals, Inc. | AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference aveooncology.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RILOGROTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650377 ↗ |
| Known as | AV-380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04815551 ↗ |
| Known as | Av-380 (gdf15 mab) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650377 ↗ |
| Modality | Monoclonal antibody | “AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb)” NCT04815551 ↗ |
| Route | Intravenous | “IV infusion of AV-380 at dose level 4 mg/kg” NCT04815551 ↗ |
| Target | GDF15 | “intended to bind circulating human growth differentiation factor 15 (GDF-15)” NCT04815551 ↗ |